企业QQ
官方微信
蚂蚁淘生物是一家专门从事抗体,蛋白,细胞等试剂产品研发与销售的公司.蚂蚁淘生物专业代理NeoCloneX 品牌试剂,大量现货,保证正品,价格优惠.欢迎来询
About NeoCloneThrough a lot of hard work, a license from the Wisconsin Alumni Research Foundation (WARF) and a desire to have an impact on human health, NeoClone was founded in 1999 by three University of Wisconsin scientists who recognized the need for better ways to discover and develop antibodies. As they refined the process to make better antibodies (what is now the NeoAb process), they established a service business to make high-quality antibodies for others. By 2002 the founders realized a need to bring in business expertise to help grow the company by leveraging its ability to make excellent antibodies. This change in direction is the foundation of what NeoClone is today - a company focused on developing high quality antibodies for sale as reagents and establishing partnerships and collaborations to develop diagnostics. As a result of these efforts, we now have over 1000 customers in 30+ countries. To poise ourselves for future success, we've continued to refine our antibody development abilities. In 2014, we added antibody phage display technology to help us develop the diverse and specific antibody repertoire to certain difficult targets that might be difficult to achieve with hybridoma technology alone. We have developed camelid (VHH) antibody capabilities so we can service the rapidly growing therapeutics market. We have been offering this service since 2015. Want to know more? Deven McGlenn, NeoClone's CEO, will be happy to help. |
苏州蚂蚁淘生物科技有限公司为NeoCloneX品牌在华授权代理商，公司不仅坚持提供传统标记的二抗（如酶标记，AMCA，FITC，罗丹明，Cy系列等），而且始终与*的染料生产商合作，以最快的速度供应新型染料标记的二抗（如Alexa Fluor，DyLight 405）。若您对Neoclone INCX产品感兴趣，请致电 0512-67156496 了解详情
NeoClone's Management Team Deven McGlenn - Chief Executive Officer Deven McGlenn is CEO of NeoClone and has been involved with the company since inception in 1999 and full-time since April 2002. During his tenure he has grown the business to $7M+ in revenues, 15+ FTEs and raised over $2.5M in equity. Prior to NeoClone, he was a management consultant for Arthur Andersen where he helped Fortune 500 companies develop a strategic view of their risk profiles. Before Andersen, he was the founder and CEO of an environmental remediation firm headquartered in the Midwest. Deven has a BS in Political Science with a minor in Business Administration from Marquette University. Contact Deven directly. Mark Sullivan, PhD - Director of Phage Technologies Dr. Sullivan is the Director of Phage Technologies at NeoClone. He has years of experience manipulating immunoglobulin molecules to develop novel reagents using phage antibody technology. Dr. Sullivan is an expert in the creation of scFv libraries using novel strategies that eliminate common problems associated with production and use of complex Ab libraries. Mark has worked at the University of Rochester, Johnson & Johnson and Eastman Kodak. He received his PhD from the University of Wisconsin-Madison and his BS from Purdue University. For questions relating to antibody phage display, please contact Mark.